Medical Science

Khan R, Javed I, Shahid S, Ibrahim N, Ayesha M, Zamir M, Fazal M, Wajid F, Atif A, Ul-Ain Q, Jabbar Z, Iqbal MZ. Systematic review of the impact of collaborative care on the progression of disease complications in the management of Hypertension in Asia. Medical Science 2024; 28:

doi: https://doi.org/10.54905/disssi.v28i146.e28ms3325

Authors' Affiliation:

¹Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan ²Department of Pharmacy, Faculty of Natural Sciences, Forman Christian College (A Chartered University), Lahore, Punjab, Pakistan ³Research Student, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan

*Corresponding Author

Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan

Email: drmmziqbal@gmail.com

Peer-Review History

Received: 26 January 2024 Reviewed & Revised: 30/January/2024 to 04/April/2024 Accepted: 08 April 2024 Published: 15 April 2024


Peer-review Method

External peer-review was done through double-blind method.

Medical Science pISSN 2321-7359; eISSN 2321-7367



© The Author(s) 2024. Open Access. This article is licensed under a Creative Commons Attribution License 4.0 (CC BY 4.0)., which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.



Rabeel Khan¹, Iqra Javed², Sara Shahid¹, Nasreen Ibrahim³, Maryam Ayesha³, Maryam Zamir³, Muntaha Fazal³, Fatima Wajid³, Ayesha Atif³, Qurat-ul-Ain, Zeeshan Jabbar³, Muhammad Zahid Igbal^{1*}

ABSTRACT

Background: Asian countries exhibit a high prevalence of hypertension., substantially increasing the burden of cardiovascular diseases owing to variables such as lifestyle choices, eating habits, and genetic dispositions. Objective: The systematic review evaluates the effectiveness of collaborative care approaches in the treatment of hypertension and the corresponding complications, emphasizing the significance of interdisciplinary healthcare teams in enhancing patient outcomes. Methodology: The researchers conducted a systematic evaluation using several search engines to find intervention-based experimental studies. A comprehensive search was carried out using one or more of the following online databases: Web of Science, Google Scholar, Science Direct, Pro Quest, Pub Med, Research Gate, and Scopus. The research group conducted this systematic review following the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)" guidelines. Results: This review incorporated the latest research findings ranging from 2003 to 2023. The present review included a total of 20 studies that met the specified criteria out of 2334 studies. Interventions that involve collaboration among healthcare professionals, such as pharmacists, nurses, and dietitians in Asia, resulted in significant decreases in both systolic and diastolic blood pressure among individuals. We used the ZEE tool to evaluate the quality and relevancy of the research. Conclusion: The review demonstrates the effectiveness of the collaborative care framework and emphasizes the need for a multidisciplinary approach in educating patients.



Health care providers such as nurses, pharmacists, and dietitians play an important role in providing personalized guidance optimized to each patient's needs, which improves hypertension management.

Keywords: Hypertension, Disease complications, Blood pressure, Cardiovascular risk, collaborative care, hypertension in Asia

1. INTRODUCTION

Hypertension, also referred to as elevated blood pressure, is a major health problem that has a substantial impact on cardiovascular health. It is defined by elevated levels of blood pressure, with a systolic range of 120 to 139 mmHg and a diastolic range of 80 to 89 mmHg in the prehypertensive stage, impacting individuals of all age cohorts. The disease is a significant cause of premature death worldwide; Cardiovascular, diseases are the leading cause of death globally (Chang et al., 2021). According to data from the World Health Organization (WHO), 17.9 million deaths worldwide were attributed to cardiovascular diseases (CVDs) in 2019, making cardiovascular diseases the primary cause of death globally (Reddy and Mathur, 2021).

In addition, a recent World Heart Federation analysis showed that the number of deaths from CVD increased from 12.1 million in 1990 to 20.5 million in 2021. Approximately 80% of cardiovascular disease (CVD) casualties take place in low- and middle-income nations. The research highlighted that hypertension, atmospheric pollution, smoking, and increased levels of LDL cholesterol are significant factors leading to cardiovascular disease mortality (Lee and Hendriks, 2023). Hypertension, or high blood pressure, is influenced by several variables, including poor lifestyle habits such as an inadequate diet, insufficient physical exercise, and tobacco use. These behaviors not only elevate the likelihood of developing hypertension but also aggravate the difficulty of controlling it. Furthermore, the presence of stress, despair, and anxiety can negatively affect the regulation of blood pressure. Additionally, those with a genetic predisposition and those who are obese are at an even higher risk of developing elevated blood pressure (Shyuan et al., 2020).

In Asia, specifically in nations such as India, Pakistan, and China, there is a substantial incidence of hypertension. A considerable percentage of the population in these countries lacks an understanding of hypertension and does not have sufficient access to healthcare services (Jafar et al., 2009). Uncontrolled hypertension may result in severe problems, including life-threatening cardiovascular events such as heart disease and stroke. Although hypertension is a serious condition, it is frequently not detected, particularly in older persons, since it does not often cause noticeable symptoms. Early identification and therapy are crucial in preventing the spread of complications caused by this silent killer (Hari et al., 2021). Multidisciplinary care models have emerged as an effective strategy to manage hypertension and its related risks. These models emphasize the importance of a team approach in offering holistic treatment that tackles the multifaceted aspects of hypertension.

By focusing on collaborative care, these models aim to improve blood pressure control and reduce cardiovascular issues through patient education, support for lifestyle changes, and regular monitoring (Haghighat and Salehi, 2015). The high prevalence of hypertension in Asia, together with the growing incidence of cardiovascular diseases, highlights the immediate need for efficient treatment measures. This systematic study aims to investigate the influence of collaborative care on the progression of disease complications in the treatment of hypertension in Asia. The review seeks to analyze current research and data to emphasize the advantages of a cooperative approach and provide valuable insights on its successful implementation in various healthcare environments. The aim is to make a valuable contribution to the ongoing efforts to enhance the treatment of hypertension and ultimately reduce the global burden of cardiovascular diseases.

2. MATERIALS AND METHODS

The methodology for this systematic review primarily involved searching online databases to locate and identify a significant number of studies conducted on the impact of collaborative care in managing complicated cases of Hypertension in Asian regions: For this review, we actively searched through Science Direct, PubMed, Web of Science, Scopus, Directory of Open Access Journals, and ProQuest. We also conducted manual searches using Google Scholar. Furthermore, we evaluated the studies using the ZEE tool and ensured that the research protocols followed the principles outlined in the PRISMA flow statement.

The search terms used to locate these research studies included "Collaborative healthcare", "Integrated health care", "Management of uncontrolled hypertension", "Role of Pharmacist", "Role of Nurses", "Role of Physicians", "Role of nutritionists", "Therapeutic interventions for hypertension," "Pharmacological interventions for hypertension," "Lifestyle interventions for controlling hypertension", "Interventional approaches to hypertension management", "Nutritional interventions for hypertension", and "hypertension in Asia". The search included studies within the period, from 2003 to 2023. Out of the 2334 studies identified, we included only 20 in the systematic review based on their adherence to the inclusion criteria.

Inclusion Criteria

The inclusion criteria were as follows:

The studies were from Asia.

The studies included patients of hypertension (with or without complications).

The studies selected were intervention-based experimental studies.

The studies published were in English.

Exclusion Criteria

The Exclusion criteria were as follows:

Studies not conducted in Asia.

Studies that did not include hypertensive patients.

The studies involved alternative therapy methods, such as acupuncture, Ayurvedic, or homeopathic medicines.

The studies without before-and-after measurements of blood pressure.

Studies not published in English.

Data Extraction

The information gathered from these investigations included details on the authors, the country of the research, the year the study was conducted, the number of participants or the population involved, the structure of the study, the interventions implemented during the experiment, and the effects of these interventions on the participants' systolic and diastolic blood pressures. The ZEE tool served as a checklist for evaluating the quality of included studies.

Data Synthesis and Analysis

We paid particular attention to understanding the significance of healthcare workers in handling hypertension and its associated complications. We achieved this by carefully examining their interventions in the study and assessing their impact on different health indicators, including systolic and diastolic blood pressure, LDL cholesterol levels, triglyceride levels, and HbA1C levels. The findings and subsequent discussions underscored the beneficial effects of collaborative care in controlling hypertension.

3. RESULTS

Through searches in electronic databases, we discovered 2,334 original research articles in total following the removal of duplicates and unsuitable records, 1,645 articles underwent screening. We excluded 1,393 articles after reviewing their titles and abstracts for relevance to our keywords, leaving 252 studies for further consideration. We attempted to retrieve 252 of these studies, but could not access 103 studies; this included 63 conference proceedings and 53 case studies. Consequently, we reviewed 139 studies for suitability. The full texts of 15 studies were unavailable, we excluded 48 studies because they were published more than 20 years ago. Additionally, we excluded 56 studies that did not meet the inclusion criteria. Ultimately, we selected 20 research articles for inclusion in the review. For detailed data extraction information, refer to the PRISMA Chart depicted in (Figure 1).




Figure 1 PRISMA flow diagram for systematic review

Different tools are available to assess the quality of various study designs. These include the adaptation of the Newcastle-Ottawa scale (NOS) for cross-sectional studies, the Johanna Briggs Institute checklist (JBIC) specifically for analytical cross-sectional research, the NIH quality assessment tool (NIH-QAT) suitable for both observational cohort and cross-sectional studies, and the ZEE tool, which is applicable to cross-sectional, observational, qualitative, and randomized controlled trials (RCTs). Introduced in 2016, the ZEE tool, often referred to as ZEE 20, comprises a 20-item questionnaire designed to evaluate crucial aspects of cross-sectional, observational, qualitative, and randomized controlled trials (RCTs). This includes the study's design, the rationale behind the sample size, the target demographic, the sampling method, the validity and reliability of the research, and the study's overall methodological approach.

The table presents the results of our analysis on the included studies, conducted using the ZEE tool (Table 1 ZEE Tool). Our analysis detailed critical aspects of the studies, including their geographical settings, participant numbers, survey lengths, methodological

designs, follow-up procedures, applied interventions (like educational initiatives, treatment changes, or lifestyle adjustments), and the outcomes of these interventions. Most of the studies we reviewed were Randomized Controlled Trials (RCTs), with some incorporating survey-based and interview-based quantitative analyses. Additionally, our review covered a Retrospective Cohort study, a Case-Control study, and an open-label, single-arm trial. In the studies analyzed, a notable portion explicitly defined their goals.

The majority reported no conflicts of interest. A small portion disclosed their funding sources, while the bulk did not. The researchers provided justification for the sample size and was provided in only seven out of the total number of studies. Among the 20 studies reviewed, four originated from Malaysia, three were conducted in India, another three in China, three took place in Iran, two in Japan, two in Turkey, and one each in Singapore, Pakistan, Bangladesh, and Sri Lanka combined, and another in various other developing nations. The duration of these studies varied, with the longest extending over three years and the shortest spanning just a few days.

Zee Tool for Cross-sectional Study Evaluation

The Zee tool, a modified and validated version of the AXIS tool, serves as a crucial instrument for critically appraising cross-sectional studies. It systematically assesses their trustworthiness, importance, and relevance in clinical research. This tool is notable for its thorough approach in evaluating the quality of observational interventional studies, encompassing both cohort studies and case-control studies. This tool is essential for assessing the credibility, relevance, and reliability of clinical research findings, as detailed in (Table 1).

Table 1 Represents the Zee tool

Study	1 (Mi ao et al., 202 0)	2 (Ca kir & Pin ar 200 6)	3 (Shi ma et al., 201 4)	4 (De vi et al., 201 1)	5 (Ka nda sam y et al., 201 6)	6 (We i and Om ar, 201 7)	7 (Jaf ar et al., 200 9)	8 (Al i et al., 202 0)	9 (Li et al., 202 1)	10 (Hu et al., 202 3)	11 (Eg hb ali- Ba ba di et al. 201 8)	12 (Sh yu an et al., 202 0)	13 (Jaf ar et al., 201 7)	14 (Chu a et al., 2012	15 (Zh ao et al., 201 2)	16 (Sian g et al., 2019	17 (Kor dvar kane et al., 2023	18 (Ka wam ura et al., 2016	19 (Akit a et al., 2003	20 (Mas lakp ak et al., 2018
Clarification of Objectives: Ensuring Clear Understanding of Study Goals and Aims	V	V	V	V	V	√	√	√	√	V	√	√	√	V	V	V	V	V	√	√
Alignment of Study Aims with Design: Evaluation of Consistency Between Research Objectives and Study Methodology	V	V	V	V	V	V	×	V	V	√	√	√	V	V	V	V	V	V	√	√
Justification of Sample Size: Assessing the Rationale Behind the	×	×	×	×	V	V	×	×	V	×	√	√	V	×	×	×	×	×	×	×

									I								1			
Determination of																				ı
Participant Numbers		<u> </u>	<u> </u>																	<u> </u>
Clarity of Target																				
Population																				ı
Definition:																				ı
Evaluation of the																				
Precision and	$\sqrt{}$	×	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	×	×	\checkmark	×	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	×	$\sqrt{}$	$\sqrt{}$	×	$\sqrt{}$	×	\checkmark
Transparency in																				ı
Identifying the																				ı
Study's Intended																				
Population																				
Relevance of Study																				
Sample to Target																				
Population:																				
Assessment of the																				
Appropriateness and	$\sqrt{}$	×	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	V	×	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	×	$\sqrt{}$	V	$\sqrt{}$	×	×
Representativeness of			,	,	,	,	,	·		,	,	·	·	·		,				
the Sample in																				
Relation to the																				
Intended Population																				
Relevance of Selected	-	 	<u> </u>																	
Population to Sample																				
Size: Evaluation of	,	,	,		,				√	,	1	,	,		$\sqrt{}$	1	,	,	1	ı
the Applicability and	٧	$\sqrt{}$	$\sqrt{}$	×	$\sqrt{}$	×	×	×	V	$\sqrt{}$	$\sqrt{}$	\checkmark	V	×	٧	\checkmark	√	√	\checkmark	×
Sufficiency of Sample																				
Size in Representing																				
the Target Population		<u> </u>	<u> </u>																	
Addressing and																				
Categorizing Non-																				
Responders:	\checkmark	×	×	$\sqrt{}$	$\sqrt{}$	×	×	×	×	×	$\sqrt{}$	$\sqrt{}$	×	×	×	$\sqrt{}$	$\sqrt{}$	×	×	\checkmark
Strategies and																				
Measures																				
Assessment of																				
Appropriateness:																				
Risk Factor and																				
Outcome Variable	$\sqrt{}$	×	$\sqrt{}$	×	$\sqrt{}$	\checkmark	×	\checkmark	$\sqrt{}$	\checkmark	$\sqrt{}$	$\sqrt{}$	\checkmark	$\sqrt{}$	×	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	\checkmark
Measurement in																				
Relation to Study																				
Aims																				
Validity of																				
Measurement:]																			
Utilization of																				
Established	$\sqrt{}$	×	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	×	1	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	×	$\sqrt{}$	√	V	$\sqrt{}$	$\sqrt{}$
Instruments for										•	,					,				
Assessing Risk																				
Factors and Outcome																				
1 actors and Outcome		<u></u>	<u></u>]		

xz · 11		1	1	1	l	l	1	l	l				l					1	1	
Variables																				
Clarity in Statistical Significance and Precision Estimation Determination: Utilization of Metrics such as p-values and Confidence Intervals	√	√	V	×	×	√	×	×	V	√	×	V	√	×	√	√	√	√	√	×
Adequacy of Method Description for Replicability: Ensuring Sufficient Detail in Statistical and Procedural Explanations	×	V	×	×	×	V	×	V	V	$\sqrt{}$	×	×	V	√	\checkmark	×	×	√	V	×
Adequacy of Basic Data Description: Ensuring Sufficient Detail in Presenting Fundamental Data Characteristics	√	×	V	√	√	V	V	×	V	×	V	V	√	√	√	√	×	√	×	V
Concerns Regarding Non-Responsive Bias: Evaluation of Response Rate Implications	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Description of Non- Responder Information: Appropriateness and Completeness of Reporting on Non- Responders	×	×	V	×	×	×	×	×	V	×	×	×	×	×	×	√	√	×	×	×
Internal Consistency of Results: Evaluation of Coherence and Harmony Within the Study Findings	√	V	V	V	V	V	×	V	V	√	√	V	V	×	√	√	√	V	V	V
Comprehensive Presentation of Results: Ensuring Inclusion of All Analyses Described in the Methodology	V	×	V	×	V	V	×	V	V	V	V	V	V	V	×	√	V	V	V	V
Alignment of	$\sqrt{}$	×	1	1	1	×	V	V	1	1	V	1	1	V	×	V	V	V	V	V

Discussion and																				
Conclusions with																				
Results: Assessing																				
the Appropriateness																				
of Authors'																				
Interpretations Based																				
on Study Findings																				
Influence of Funding																				
Sources and Conflict																				
of Interest on Author																				
Interpretation:	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×	×
Examination of																				
Potential Biases in																				
Result Interpretation																				
Ethical Approval and																				
Participant Consent:																				
Assessment of																				
Compliance with	$\sqrt{}$	$\sqrt{}$	\checkmark	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	\checkmark	$\sqrt{}$	$\sqrt{}$	\checkmark	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$	\checkmark	\checkmark	$\sqrt{}$	$\sqrt{}$	$\sqrt{}$
Ethical Standards																				
and Consent																				
Procedures																				

Table 2 Study characteristics of the included studies

Sr	Study	Country	Study Duration	Sample Size (N)	Study type	Follow Up's	Intervention	Outcome
1.	(Miao et al., 2020)	China	12 weeks	N=156	Single-blind, randomized controlled trial	In every two weeks	In this study, Nurse-led intervention. Nurses provide guidelines to patients through phone calls or home visits. Top of Form The guidelines include change in lifestyle, quit smoking, regular exercise	Systolic blood pressure by interventions decrease up to 15.03±23.75 mm Hg. And Diastolic blood pressure decreases up to 8.54±8.86 mm hg.
2.	(Cakir & Pinar 2006)	Istanbul, Turkey	26 weeks	N = 70	Randomized controlled trial	Two months	This study involves a self- directed intervention with guidance from healthcare professionals.	The mean reductions in SBP were 8.8 (SD = 5.2) and DBP were 6.9 (SD = 5.3) mmHg.

			<u> </u>		<u> </u>			
							Interventions	
							include limiting	
							sodium intake,	
							exercising, quit	
							smoking, and	
							reducing alcohol	
							consumption.	
							Healthcare	
							professionals	
							conduct a 45-	
							minute interview	The study helps
							with each patient	to find
							to discuss in	symptoms of first
					Quantitative		detail the causes	diagnosis, barrier
	(Shima et al.,				analysis,	Not	and factors	in hypertension
3.	2014)	Malaysia	12 weeks	N=25	interview	mentioned	leading to high	care, and non-
	,				base		blood pressure.	adherence
					2450		The patients are	attitude of the
							then recalled for	patient towards
							follow-up, and	treatment.
							the results are	treatment.
							analyzed	
							quantitatively.	
							Participants were	
							randomly	
							assigned to	
							groups and	The group with a
					Randomized,	Seven	treated with	higher dose gives
4.	(Devi et al.,	India	8 Weeks	N=402	open-label	visits in 8	varying dose	better results in
	2011)				parallel trial	weeks	strengths of a	the reduction of
					P	.,, 555.5	combination of	blood pressure.
							medications,	7 F
							specifically	
							amlodipine and	
							metoprolol XL.	
							During the first	In this study,
							follow-up,	there was a
							pharmacists	reduction of SBP
							provided patients	
	/IZ 1 .	Court			Randomized	Two	with information	in the
5.	(Kandasamy	Southern	26 weeks	N=60	controlled	follow-ups	about	intervention
	et al., 2016)	India			study	per month	hypertension,	group from a
						_	including its	starting of
							causes, normal	150.13±25.670 to
							values, and	a final follow-up
							diagnosis, along	of 145.33±12.914
L]	anagnosis, along	

							with advice on lifestyle modifications. In the second follow-up, pharmacists enhanced the patients' understanding of potential medication complications and dietary planning.	
6.	(Wei and Omar, 2017)	Malaysia	Few days	N=200	Survey base study	No follow up	Physicians make pharmacological and non-pharmacological interventions to control blood pressure. Non-pharmacological interventions encompass lifestyle modifications, such as cessation of smoking and dietary improvements. Additionally, caregivers educated hypertension patients about the risk factors associated with the condition.	This survey reveals that patients in nursing care facilities effectively manage their blood pressure, primarily through non-pharmacological activities.
7.	(Jafar et al., 2009)	Developing countries	2years	N=1341	Randomized controlled study	Follow- up after every 3 months	Healthcare workers advise patients on maintaining a normal body weight, regulating salt	Systolic blood pressure decreases up to 10.8mm of Hg and Diastolic blood pressure decrease up to

							intake, engaging in physical activity, quit smoking, consuming fruits and vegetables essential for hypertensive patients, and reducing fat intake.	6mm of Hg.
8.	(Ali et al., 2020)	India	3 years	N=404	Parallel, open- label, pragmatic randomize d clinical trial	Every 6 months.	Intervention aims to focus on decreasing depression and stress of patients. Caregiver are giving counselling about day-to-day activities, dietary interventions, social behavior, exercises, and not to take tobacco.	Patient's blood pressure decreases by about 5 percent.
9.	(Li et al., 2021)	China	3–6 months	N=636	Comparative randomized controlled trial	Two	The Pharmacist's involvement consists of a baseline blood pressure check, patient education, prescription adjustment, guidance for physicians, and a monthly review of drugs. A questionnaire was used to gauge participant knowledge and medication adherence both before and after the experiment	The study found that the intervention group experienced a decrease in systolic blood pressure by 6.65 mmHg and a decrease in diastolic blood pressure by 7.26 mmHg.

10.	(Hu et al., 2023)	Singapore	18 months	N=1,783	Retrospective cohort study.	Two	The collaborative care team ensured that the patients were promptly screened for issues connected to type-2 diabetes, while physicians and pharmacists reviewed the medication. The patient received guidance from the clinical nurse regarding lifestyle adjustment and preventive health, while the collaborative team scheduled the subsequent appointment and	The intervention significantly reduced the SBP by 1.74 mmHg. Significantly reduced LDL-cholesterol by 0.085 mmol/L and HbA1c was significantly reduced by 0.19% in the ICT group compared with the UC group.
11.	(Eghbali- Babadi et al. 2018)	Iran	6 Months	N=190 N=334	A Randomized Controlled Trial.	Two months	hospital referrals as needed. The interventions by doctors and pharmacists included definitions training, risk factors for complications, preventions, both pharmacological and non-pharmacological treatments for BP and advice on leading a healthy lifestyle The actions of	The study demonstrated that for 56.4% of the subjects in the intervention group and 61.5% of those in the control group, the mean SBP was below 140 mmHg and the mean DBP was below 90 mmHg.

	-1 2020)				1			
	al., 2020)				case-control	months	physicians and	medication non-
					study		pharmacists are	adherence had
							to provide all	11.36 times
							hypertensive	higher and
							patients with a	Clinical inertia
							brief, validated	increased 7.82
							questionnaire to	times the odds of
							complete the	uncontrolled
							medication	hypertension.
							adherence	
							assessment.	
							Government	
							community	
							health workers	
							(CHWs) will	
							provide home	
							health education.	
							BP monitoring	
							and stepped-up	
							referral to a	
							trained general	The study
							practitioner using	observed a
		Bangladesh,			Cluster	Two	a checklist	reduction in SBP
13.	(Jafar et al.,	Pakistan	24	N=2550	randomized	months	Hypertension	by 3 mm Hg in
	2017)	and	months		controlled		management	one country and
		SriLanka			trial.		training for	by 9 mm Hg in
							public and	the other two
							private	countries.
							providers.	
							Government	
							clinics will	
							designate	
							hypertension	
							care coordinators	
							and hypertension	
							triage counters.	
-				-			In this study, the	
							pharmacist	The interventions
							counseled the	made by the
								pharmacists
	(Clause at 1		Civ		Controll	Errom Com	patients about	significantly
14.	(Chua et al.,	Malaysia	Six	N= 477	Controlled	Every four	medication,	improved the
	2012)		months		trial	week	educated the	medication
							patients about	adherence and
							their disease state	reduced systolic
							and	blood pressure
							recommended a	1

China Six months N-278 Prospective, randomized, months N-278 Prospective, randomized, months N-278 N-2								change in dose or	
China Six months N=278 Prospective, randomized, controlled study Prospective the dosage, Modified the dosage do the dosage do the dosage do the dosage do the dosage de									
China Six months N=278 Prospective, randomized, controlled study Prospective months N=28 After every two months N=28 A single center, prospective convenient sampling A single center control group A to the every two of the anti- hypertensive agent, Escalated the dosage, Modified the dosage of the anti- hypertensive medication, Transitioned to a decrease of 1.8 mmHg in the intervention group and then 1.8 mmHg in the intervention group and then 1.8 mmHg in the intervention group and then 1.8 mmHg in the control group and then 1.8 mmHg in the intervention programs, which include education and distollation and distoll								1 1	
15. (Zhao et al., 2012) China Six months N=278 Prospective, randomized, controlled study After every two months Six months N=45 A single center, prospective convenient sampling Two paramacological management of hypertension with a additional anti-hypertensive agent, Escalated the dosage, Modified the dosing schedule of the anti-hypertensive medication, Transitioned to a different medication, Transitioned to a different medication, Transitioned to a different medication within the same pharmacological class to achieve better blood pressure control and either Reduced the dosage of the anti-hypertensive drug to mitigate side effects. A single center, prospective convenient sampling Two programs, which include education about hypertension Pharmacological interventions (Pharmacological interventions) (Pharmacological interv									
Cancellar Canc								*	
The DBP Controlled study China Six months N=278 Prospective, randomized, controlled study After were two months Six months N=45 A single center, 2019 Malaysia Six months N=45 Malaysia Malaysia Malaysia Six months N=45 Malaysia Malaysi									
15. (Zhao et al., 2012) China Six months N= 278 months N= 278 months N= 278 months N= 28 months									
15. (Zhao et al., 2012) China Six months N= 278 Prospective, randomized, controlled study After every two months After									
15. (Zhao et al., 2012) China Six months N= 278 Prospective, randomized, controlled study After every two months N= 278 Prospective, randomized, controlled study After every two months Six months N= 45 A single center, prospective convenient sampling Two planning and the study Two planning and the study A single center, prospective convenient sampling Two planning and the study A single center, prospective convenient sampling Two planning and the study At the end of the skudy, the dosage, Modified the dosage,									
(Zhao et al., 2012) China Six months N= 278 Prospective, randomized, controlled study After every two months After every two different medication program with intervention son follow ups of the control group and then Tamasicanon After every two months After every two months After ever									A
15. (Zhao et al., 2012) China Six months N= 278 Prospective, randomized, controlled study Prospective, randomized, controlled study After every two months After every two adiates to a believe to the total and the provide to the adiates to a disease to a disea								_	
15. (Zhao et al., 2012) China Six months N= 278 mont								_	-
Cana et al., 2012 China Six months N= 278 Prospective, randomized, controlled study After every two months									
China China China Six months N=278 Prospective, randomized, controlled study After every two months After								_	-
Cano et al., 2012 China China Six months N=278 N=2									- C
15. (Zhao et al., 2012) China Six months N= 278 months Malaysia Malaysia Malaysia N= 278 months Malaysia Mala								· -	
15. (Zhao et al., 2012) China Six months N= 278 months						Prospective.		·	~ -
2012) China months N=278 controlled study China months N=278 controlled study Malaysia Six months Six months Malaysia Six months Six months N=45 Malaysia China months N=45 Malaysia Controlled study Controlled study Controlled study Controlled study Malaysia Controlled study Malaysia Controlled study Malaysia Malaysia A single center, prospective convenient sampling Malaysia Malaysia Six months N=45 Malaysia A single center, prospective convenient sampling Two follow ups for medication about hypertension pharmacological interventions Quality use of medication four months of interventions, only the systolic blood pressure showed a significant Systolic and diastolic blood pressure initially reduced to 146.6 ± 11.1 mmHg and 87.6 ± 9.6 mmHg, respectively. However, after four months of interventions, only the systolic blood pressure showed a significant		(Zhao et al.,		Six		_	After		_
study months medication within the same pharmacological class to achieve better blood pressure control and either Reduced the dosage of the anti-hypertensive drug to mitigate side effects. Systolic and diastolic blood programs, which include education about hypertension Pharmacological interventions group, compared to a decrease of 1.8 mmHg in the control group. Systolic and diastolic blood programs, which include education about hypertension Pharmacological interventions Quality use of medication Non- pharmacological interventions quality use of medication Non- pharmacological on the interventions programs, which include education about hypertension Pharmacological interventions Quality use of medication only the systolic blood pressure showed a significant	15.	,	China		N= 278	*	every two		
16. (Siang et al., 2019) Malaysia Six months N= 45 Six months N= 45 Pharmacological class to achieve better blood pressure control and either Reduced the dosage of the anti-hypertensive drug to mitigate side effects. Systolic and diastolic blood pressures were include education about hypertension mmHg and 87.6 ± 9.6 mmHg, respective convenient sampling Two follow ups convenient sampling Two follow ups pharmacological interventions (Quality use of medication Non-pharmacological management of hypertension only the systolic blood pressure showed a significant Six months of interventions, only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure showed a significant Six months of interventions only the systolic blood pressure Six months of interventions only the systolic blood pressure Six months of interventions		_==,		1110111110			months		
16. (Siang et al., 2019) Malaysia A single center, prospective convenient sampling Two follow ups Convenient sampli						stady		within the same	-
better blood pressure control and either Reduced the dosage of the anti-hypertensive drug to mitigate side effects. Systolic and diastolic blood pressures were initially reduced to 146.6 ± 11.1 mmHg and 87.6 ± 9.6 mmHg, respective convenient sampling A single center, prospective convenient sampling Two follow ups of medication pharmacological interventions, only the systolic blood pressure showed a significant								pharmacological	mmHg in the
16. (Siang et al., 2019) Malaysia Malaysia Malaysia Malaysia Six months N= 45 Malaysia M								class to achieve	intervention
16. (Siang et al., 2019) Malaysia Malaysia Six months N= 45 Malaysia Malaysia Six months N= 45 Malaysia Malaysia Malaysia Six months N= 45 Malaysia Malaysia Malaysia Six months N= 45 Malaysia A single center, prospective convenient sampling A single center, prospective convenient sampling Two follow ups of medication programs, which include education about hypertension pharmacological interventions Quality use of medication four months of interventions, only the systolic blood pressure showed a significant								better blood	group, compared
Reduced the dosage of the anti-hypertensive drug to mitigate side effects. Systolic and diastolic blood programs, which include education about hypertension (Siang et al., 2019) Malaysia Six months N= 45 N= 45 A single center, prospective convenient sampling Two follow ups control group. Reduced the dosage of the anti-hypertensive drug to mitigate side effects. Systolic and diastolic blood pressures were initially reduced to 146.6 ± 11.1 mmHg and 87.6 ± 9.6 mmHg, respectively. However, after four months of interventions, only the systolic blood pressure showed a significant								pressure control	to a decrease of
dosage of the anti-hypertensive drug to mitigate side effects. Systolic and diastolic blood programs, which include education about hypertension prospective convenient sampling A single center, prospective convenient sampling Two follow ups Quality use of medication pharmacological interventions (part of the pharmacological management of hypertension pharmacological management of hypertension showed a significant significant								and either	1.8 mmHg in the
anti-hypertensive drug to mitigate side effects. Systolic and diastolic blood pressures were initially reduced education about hypertension Malaysia Six months N= 45 N= 45 N= 45 A single center, prospective convenient sampling Two follow ups Floating to mitigate side effects. Systolic and diastolic blood pressures were initially reduced education about hypertension Pharmacological interventions Quality use of medication four months of interventions, only the systolic blood pressure showed a significant								Reduced the	control group.
drug to mitigate side effects. Systolic and diastolic blood pressures were include education about hypertension N= 45 Malaysia Six months N= 45 N= 45 A single center, prospective convenient sampling N= 45 N= 45 N= 45 A single center, prospective convenient sampling Two follow ups follow ups follow ups Quality use of medication four months of interventions, only the systolic blood pressure swere include education about hypertension Pharmacological interventions Quality use of medication Non- interventions, only the systolic blood pressure showed a significant								dosage of the	
Systolic and diastolic blood pressures were include education about to 146.6 ± 11.1 hypertension mmHg and 87.6 enter, prospective convenient sampling N= 45 Malaysia Malaysia Malaysia Malaysia Six months N= 45 A single center, prospective convenient sampling N= 45 A single center, prospective convenient sampling Two follow ups follow ups of medication four months of interventions, pharmacological management of hypertension showed a significant								anti-hypertensive	
(Siang et al., 2019) Malaysia Six months N= 45 Malaysia A single center, prospective convenient sampling A single center, prospective convenient sampling Two follow ups follow ups however, after four months of interventions, only the systolic management of hypertension Non- pharmacological management of hypertension showed a significant								drug to mitigate	
(Siang et al., 2019) Malaysia Malaysia Malaysia Malaysia Malaysia Malaysia Six months N= 45 Malaysia Six months N= 45 Malaysia N= 45 Malaysia Malaysia Malaysia Malaysia Malaysia Malaysia Six months N= 45 Malaysia N= 45 Malaysia N= 45 Malaysia Malaysia A single center, prospective convenient sampling Two follow ups follow ups Quality use of medication four months of interventions, only the systolic blood pressure showed a significant Malaysia N= 45 Malaysia N= 45 Malaysia N= 45 Malaysia N= 45 Malaysia A single center, prospective convenient sampling Two follow ups follow ups A single reducation about hypertension Pharmacological interventions four months of interventions, only the systolic blood pressure showed a significant								side effects.	
(Siang et al., 2019) Malaysia Six months N= 45 Malaysia A single center, prospective convenient sampling Two follow ups Quality use of medication Non-pharmacological interventions, pharmacological management of hypertension Non-pharmacological management of hypertension Six months N= 45 A single center, prospective convenient sampling Two follow ups Ouality use of medication Non-pharmacological management of hypertension Showed a significant									Systolic and
(Siang et al., 2019) Malaysia Six months N= 45 Malaysia Malaysia Malaysia Six months N= 45 Malaysia Malaysia Malaysia Six months N= 45 Malaysia N= 45 Malaysia Six months N= 45 Malaysia N= 45 Malaysia Six months N= 45 Malaysia N= 45 N= 45 Malaysia N= 45 N= 45 N= 45 Malaysia N= 45								Health education	diastolic blood
16. (Siang et al., 2019) Malaysia Malaysia Malaysia Malaysia Six months N= 45 Malaysia Malaysia Malaysia Six months N= 45 Malaysia Malaysia Six months N= 45 Malaysia Six months N= 45 Malaysia Six months N= 45 Malaysia N= 45 Malaysia N= 45 Malaysia Six months N= 45 Malaysia N= 45 Malaysia N= 45 N= 45 Malaysia N= 45 Malaysia N= 45 N= 45 N= 45 Malaysia N= 45 N=								programs, which	pressures were
(Siang et al., 2019) Malaysia N=45 Malaysia N=45 Malaysia Malaysia N=45 Malaysia Malaysia Malaysia N=45 Malaysia Malaysia N=45 Malaysia Ma								include	initially reduced
16. (Siang et al., 2019) Malaysia N=45 Malaysia N=45 Malaysia Malaysia N=45 Malaysia Malaysia Malaysia N=45 Malaysia Malaysia N=45 Malaysia Malaysia N=45 Malaysia Two follow ups Quality use of medication four months of Non-pharmacological management of hypertension showed a significant								education about	to 146.6 ± 11.1
(Siang et al., 2019) Malaysia N= 45 Malaysia Non- Malaysia Malaysia Non- Malaysia Malaysia Non- Malaysia Malays						A oirs =1 =		hypertension	mmHg and 87.6
16. (Siang et al., 2019) Malaysia Malaysia N= 45 prospective convenient sampling follow ups follow ups Quality use of medication four months of interventions, pharmacological management of hypertension showed a significant						_	Truco	Pharmacological	± 9.6 mmHg,
Malaysia months N=45 prospective convenient sampling Polymer only the systolic management of hypertension showed a significant	17	(Siang et al.,	Male et	Six	NI. 45			interventions	respectively.
sampling medication four months of interventions, pharmacological only the systolic management of blood pressure hypertension showed a significant	16.	2019)	iviaiaysia	months	IN= 45		rollow ups	Quality use of	However, after
pharmacological only the systolic management of hypertension showed a significant								medication	four months of
management of blood pressure hypertension showed a significant						sampling		Non-	interventions,
management of blood pressure hypertension showed a significant								pharmacological	
hypertension showed a significant									
significant								_	*
								- *	significant
reduction,									reduction,

			1	1	I	1		
								reaching 140.1 ±
								10.7 mmHg.
								Medication
								adherence
								improved by
								29.3% after two
								months and by
								70.7% after four
								months of
								interventions.
								The intervention
								group showed a
					D 1	Phone	Training	significant
1 -	(Kordvarkane		Four		Randomized	follow-up	program based	reduction in
17.	et al., 2023)	Iran	months	N= 72	controlled	once every	on common sense	blood pressure
	,				trial	3rd day	model of self-	and enhanced
							regulation	self-management
								aspects
								Significant
					An open-	After one,	DASH diet for 2	reduction of SBP
	(Kawamura		Six		label single	two, three	months and after	by 23.5mmHg
18.	et al., 2016)	Japan	months	N=59	arm	and six	2 months normal	and DBP by 11.8
	2010)		1110111110		trial	months	diet for next 4	mmHg was
					VI 101		months	observed
								The DASH diet
								enhanced the
								relationship
								between mean
					A			arterial pressure
					multicenter,	Not		and urinary
19.	(Akita et al.,	Ianan	Three	N=375	randomized	mentioned	DASH diet	sodium excretion
19.	2003)	Japan	months	IN-373	feeding	clearly		more than the
					trial	Clearry		controlled diet
					triai			
								did, suggesting that the DASH
								diet has a
							Comme	natriuretic effect.
							Group	Group
					Single bind		discussions about	discussions
					randomized;		diet, physical	significantly
2.0	(Maslakpak	,	Four	N. 400	parallel-	Not stated	activities, stress	improved
20.	et al., 2018)	Iran	months	N= 100	group	clearly	management,	treatment
	, -,				controlled	,	smoking	compliance
					trial		cessation, BP	among patients
					-		monitoring, and	with
							medication	hypertension,

			adherence.	including
			Educational	adherence to
			training sessions	medication, a
			regarding	low sodium diet,
			lifestyle	and medical
			modification and	appointments.
			changing	The impact of
			attitudes	educational
				interventions on
				medical
				treatment
				compliance was
				notably greater
				in patient- and
				family-oriented
				groups
				compared to
				other groups.
				Top of Form
				Family-oriented
				patient education
				resulted in
				improving BP
				control and
				ultimately
				reduced systolic
				and diastolic
				blood pressure in
				patients with
				hypertension

4. DISCUSSION

Hypertension, which is recognized as the primary determinant for cardiovascular diseases, occurs due to the combination of social, environmental, and genetic variables. Key environmental factors contributing to health issues encompass obesity, inadequate diet, excessive salt consumption, insufficient potassium intake, and a sedentary lifestyle. Joint efforts by healthcare workers, including doctors, pharmacists, nurses, and dieticians, have proven successful in managing hypertension. This collaborative approach improves control of blood pressure, boosts compliance with treatment, motivates lifestyle changes, and aids in the surveillance of potential complications. The incidence and traits of hypertension in Asia need particular attention due to unique features such as white-coat hypertension, masked hypertension, and fluctuating blood pressure readings, which are more prevalent in this region (Kario et al., 2020).

Asia's swift economic expansion is associated with a move towards less healthy living habits, including greater intake of high-fat diets, decreased physical activity due to technological progress, and a lack of adequate health awareness. These changes contribute to rising levels of obesity and hypertension (Yang et al., 2023). This scenario highlights the need for customized management approaches in Asian nations to tackle the unique challenges and risk factors common among the population. The current systematic review concentrates on assessing the effect of collaborative care on the advancement of disease complications in the management of hypertension in Asia. The findings of the review indicate that a team-based care approach, involving doctors, pharmacists, nurses, and

dietitians, effectively reduced systolic and diastolic blood pressure levels. This approach also led to a decrease in the incidence of hypertension-related complications in Asia.

Likewise, a study from the US demonstrated that a multidisciplinary team effort, particularly involving pharmacists and nurses, has been successful in lowering systolic and diastolic blood pressure, thereby enhancing patient health (Proia et al., 2014). A separate study from the US in 2019 showed that collaborative care models between pharmacists and physicians (PPCCM) have improved average blood pressure levels and achieved a significantly increased rate of blood pressure control, reaching nearly 90%. Dixon et al., (2020) while in a pragmatic randomized controlled trial conducted in Switzerland, targeting patients with untreated hypertension, participants were divided into two groups: One received treatment-based control (TBC), At the same time another group received standard care. Following a 6-month observation period, researchers observed no significant changes in blood pressure levels. However, after 12 months, those in the TBC group demonstrated better management of systolic blood pressure, though diastolic blood pressure saw no change (Santschi et al., 2021).

This review illustrates various reasons why care delivered by a team was effective in managing the progression of complications by efficiently controlling blood pressure in patients with hypertension in Asia. By adopting a multidisciplinary strategy, healthcare professionals were able to support in managing medications, ensuring patients followed their medication regimens closely and made the required adjustments for ideal blood pressure management. Furthermore, by providing patients with education on hypertension and lifestyle changes, they were more prepared to handle their condition effectively. Our systematic review found that interventions supporting self-management of hypertension, led by nurses, significantly lowered both systolic and diastolic blood pressure. A 2005 study in the USA found that educational initiatives led by nurses significantly improved blood pressure management. This improvement resulted from patients more faithfully following their medication schedules, adopting healthier lifestyle changes, and, when possible, practicing self-monitoring of their blood pressure (Bosworth et al., 2005; Denver et al., 2003).

Face-to-face interventions seem to be more effective, at least for the reducing DBP levels (Bosworth et al., 2005). A randomized control study in Sweden found that a nurse-led secondary prevention program, using telephone follow-ups for medication adjustments, significantly improved blood pressure management more effectively than standard care (Irewall et al., 2015). Adding pharmacists to the clinical team, focusing specifically on enhancing medication strategies, led to the most significant improvements in blood pressure control. The most effective interventions featured pharmacists as essential members of the clinical team, directly contributing to the strategy and implementation of treatment. These pharmacists played a vital role in modifying prescription regimens in collaboration with physicians, evaluating patients' medication adherence, and guiding patients through lifestyle modifications to meet their health objectives.

Similarly, a study was undertaken in the USA where a clinical pharmacist was included into each office's staff. The pharmacist offered advice to both doctors and patients in the intervention offices. The objective of the investigation was to assess the potential of pharmacist assistance in enhancing blood pressure. The research shown a significant decrease in blood pressure (Anderegg et al., 2016; Carter et al., 2008; Tobari et al., 2010). This improvement likely results from the pharmacist's expertise in medication management, along with their dedication to ensuring proper drug treatment and medication adherence. In addition, pharmacists have a crucial role in advising patients on how to manage their blood pressure via lifestyle changes. Furthermore, the research conducted in Asia confirmed that using the Dietary Approaches to Stop Hypertension (DASH) diet resulted in significant reductions in both systolic and diastolic blood pressure, thereby validating the effectiveness of this dietary approach.

In addition, it is well recognized that making other changes to one's diet, such as reducing salt intake, losing weight, and moderating alcohol use, can help to decrease blood pressure. Significant research has focused on how food scientists and nutritionists contribute to managing hypertension by incorporating functional foods into diets. These experts have used the DASH diet methodology, which has shown significant efficacy in decreasing both systolic and diastolic blood pressure (Chiu et al., 2016). Additionally, previous research conducted in the United States has explored the effects of the DASH diet on blood pressure. This research consistently demonstrates that following the DASH diet leads to a notable reduction in both systolic and diastolic blood pressure (Sacks et al., 2001; Challa et al., 2023). Likewise, a study conducted in Italy discovered that following the DASH diet significantly lowered both systolic and diastolic blood pressure.

Additional findings indicated that the DASH diet also reduced the total levels of LDL cholesterol and triglycerides in people suffering from hypertension (Ravera et al., 2016). The outcomes of this systematic review, drawing from research across Asian nations, highlight the critical importance of adopting team-based care approaches to improve the management of hypertension significantly.

These findings stress the urgency for healthcare infrastructures to embrace these strategies to prevent the progression of hypertension-related complications. Future efforts should prioritize the integration and improvement of multidisciplinary teams to provide effective, patient-centered care that addresses the complex features of hypertension and its treatment, using the distinctive abilities of each team member.

5. CONCLUSION

The review underlines the benefits of team-based care in managing high blood pressure in Asia, pointing out the value of a team approach in healthcare. Reviewing 20 studies revealed that healthcare workers made efforts, including pharmacists, nurses, and nutrition experts, resulted in significant drop in the upper (systolic) and lower (diastolic) blood pressure. The actions taken by pharmacists, doctors, nurses, and other health professionals involved lifestyle changes, ensuring patients follow their medication schedules, diet adjustments, preventive strategies, and providing advice.

Research shows that following the DASH diet, along with taking preventive measures, significantly reduces blood pressure. Additionally, joint efforts from doctors and pharmacists improved health in patients with other comorbidities. Nurses enhanced the execution and regularity in keeping the disease within normal limits. Together, all healthcare workers played a part in minimizing adverse treatment results. The effective results of this method indicates that a more widespread implementation within healthcare systems is needed for the management of hypertension in patients.

Limitations of the study

A notable limitation of the review is its geographical focus on Asia, which may limit the generalizability of the findings to other regions with different healthcare systems and population dynamics. Future research could explore the scalability of collaborative care models to other regions with diverse healthcare infrastructures and examine the long-term impacts of such models on cardiovascular disease prevention and management.

Acknowledgements

We express our gratitude to the Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Lahore University of Biological and Applied Sciences, for their generous assistance and direction throughout the development of this research project.

Ethical approval

The current systematic review has been conducted after receiving approval from the university's ethical review board, with ethical procedure number ERB-PHRMD-DPP/2413-A.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Funding

This study has not received any external funding.

Conflict of interest

The authors declare that there is no conflict of interests.

Data and materials availability

All data sets collected during this study are available upon reasonable request from the corresponding author.

REFERENCES

 Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G; DASH-Sodium Trial Collaborative Research Group. Effects of the

- Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. Hypertension 2003; 42(1):8-13. doi: 10.1161/01.hyp.0000074668.08704.6e
- Ali MK, Chwastiak L, Poongothai S, Emmert-Fees KM, Patel SA, Anjana RM, Sagar R, Shankar R, Sridhar GR, Kosuri M, Sosale AR, Sosale B, Rao D, Tandon N, Narayan KMV, Mohan V; INDEPENDENT Study Group. Effect of a collaborative care model on depressive symptoms and glycated hemoglobin, blood pressure, and serum cholesterol among patients with depression and diabetes in India: the INDEPENDENT randomized clinical trial. JAMA 2020; 324(7):651-662. doi: 10.1 001/jama.2020.11747
- 3. Anderegg MD, Gums TH, Uribe L, Coffey CS, James PA, Carter BL. Physician-Pharmacist Collaborative Management: Narrowing the Socioeconomic Blood Pressure Gap. Hypertension 2016; 68(5):1314-1320. doi: 10.1161/HYPERTEN SIONAHA.116.08043
- Bosworth HB, Olsen MK, Gentry P, Orr M, Dudley T, McCant F, Oddone EZ. Nurse administered telephone intervention for blood pressure control: a patient-tailored multifactorial intervention. Patient Educ Couns 2005; 57(1):5-14. doi: 10.1016 /j.pec.2004.03.011
- Cakir, Hulya, Rukiye Pinar. Randomized controlled trial on lifestyle modification in hypertensive patients. West J Nurs Res 2006; 28: 190-209. doi.org/10.1177/0193945905283367
- Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, Hartz AJ. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich) 2008; 10(4):26 0-71. doi: 10.1111/j.1751-7176.2008.07434.x
- 7. Challa HJ, Ameer MA, Uppaluri KR. DASH Diet to Stop Hypertension. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024, 2023.
- Chang HC, Cheng HM, Chen CH, Wang TD, Soenarta AA, Turana Y, Teo BW, Tay JC, Tsoi K, Wang JG, Kario K. Dietary intervention for the management of hypertension in Asia. J Clin Hypertens (Greenwich) 2021; 23(3):538-44. doi: 10.1111/jc h.14116
- Chiu S, Bergeron N, Williams PT, Bray GA, Sutherland B, Krauss RM. Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. Am J Clin Nutr 2016; 103(2):341-7. doi: 10.3945/ajcn.115.1 23281
- 10. Chua SS, Kok LC, Yusof FA, Tang GH, Lee SW, Efendie B, Paraidathathu T. Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or

- hyperlipidaemia in primary care settings. BMC Health Serv Res 2012; 12:388. doi: 10.1186/1472-6963-12-388
- 11. Denver EA, Barnard M, Woolfson RG, Earle KA. Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with type 2 diabetes. Diabetes Care 2003; 26(8):2256-60. doi: 10.2337/diacare.26.8.22 56
- 12. Devi P, Xavier D, Sigamani A, Pandey S, Thomas T, Murthy S, Sharma K, Bosco B, Mehta K, Joshi S, Gupta R. Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS–a randomized controlled trial. Blood Press Suppl 2011; 2:5-12. doi: 10.3109/08037051.2011.617040
- 13. Dixon DL, Parod ED, Sisson EM, Van-Tassell BW, Nadpara PA, Dow A. Impact of a pharmacist-physician collaborative care model on time-in-therapeutic blood pressure range in patients with hypertension. J Am Coll Clin Pharm 2020; 3(2):4 04-409. doi: 10.1002/jac5.1115
- 14. Eghbali-Babadi, Maryam, Awat Feizi, Alireza Khosravi, Nizal Sarrafzadegan. The effect of training on knowledge, attitude, and practice in patients with hypertension; the application of the expanded chronic care model: a clinical trial study. 2018; doi.org/10.5812/ircmj.61693
- 15. Haghighat A, Salehi S. Effect of performing Collaborative Care Model on Controlling High Blood Pressure in patients referred to Semnan city's clinics, 2013. Arch Adv Biosci 2015; 6(4):1-7. doi: 10.22037/jps.v6i4.10619
- 16. Hari TYS, Sudha TYS, Varghese AM, Sasanka KK, Thangaraju P. A study of risk factors and complications in elderly hypertensive subjects. J Family Med Prim Care 2021; 10(6):223 0-4. doi: 10.4103/jfmpc.jfmpc_1959_20
- 17. Hu PL, Tan CY, Nguyen NH, Wu RR, Bahadin J, Nadkarni NV, Tan NC. Integrated care teams in primary care improve clinical outcomes and care processes in patients with non-communicable diseases. Singapore Med J 2023; 64(7):423-429. doi: 10.11622/smedj.2022067
- 18. Irewall AL, Ögren J, Bergström L, Laurell K, Söderström L, Mooe T. Nurse-Led, Telephone-Based, Secondary Preventive Follow-Up after Stroke or Transient Ischemic Attack Improves Blood Pressure and LDL Cholesterol: Results from the First 12 Months of the Randomized, Controlled NAILED Stroke Risk Factor Trial. PLoS One 2015; 10(10):e0139997. doi: 10.1371/journal.pone.0139997
- 19. Jafar TH, Hatcher J, Poulter N, Islam M, Hashmi S, Qadri Z, Bux R, Khan A, Jafary FH, Hameed A, Khan A, Badruddin SH, Chaturvedi N; Hypertension Research Group. Community-based interventions to promote blood pressure control in a developing country: a cluster randomized trial.

- Ann Intern Med 2009; 151(9):593-601. doi: 10.7326/0003-4819-151-9-200911030-00004
- 20. Jafar TH, Jehan I, De-Silva HA, Naheed A, Gandhi M, Assam P, Finkelstein EA, Quigley HL, Bilger M, Khan AH, Clemens JD, Ebrahim S, Turner EL; for COBRA-BPS Study Group; Kasturiratne A. Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial. Trials 2017; 18(1):272. doi: 10.732 6/0003-4819-151-9-200911030-00004
- 21. Kandasamy KR, Natarajan AG, Sebastian JO, Konakalla MA, Sam RO, Rajagopal SS, Ramathan S. Impact of pharmacist intervention in screening and education on blood pressure in a rural area in Southern India. Asian J Pharm Clin Res 2016; 9 (Suppl 3):339-343. doi: 10.22159/ajpcr.2016.v9s3.14782
- 22. Kario K, Chia YC, Sukonthasarn A, Turana Y, Shin J, Chen CH, Buranakitjaroen P, Nailes J, Hoshide S, Siddique S, Sison J, Soenarta AA, Sogunuru GP, Tay JC, Teo BW, Zhang YQ, Park S, Minh HV, Tomitani N, Kabutoya T, Verma N, Wang TD, Wang JG. Diversity of and initiatives for hypertension management in Asia—Why we need the HOPE Asia Network. J Clin Hypertens (Greenwich) 2020; 22(3):331-43. doi: 10.1111/jch.13733
- 23. Kawamura A, Kajiya K, Kishi H, Inagaki J, Mitarai M, Oda H, Umemoto S, Kobayashi S. Effects of the DASH-JUMP dietary intervention in Japanese participants with high-normal blood pressure and stage 1 hypertension: an open-label single-arm trial. Hypertens Res 2016; 39(11):777-85. doi: 10.1038/hr.2016.7
- 24. Kordvarkane Z, Oshvandi K, Mohammadi Y, Azizi A. Effect of education based on the Common-Sense Model of Self-Regulation on blood pressure and self-management of hypertensive patients: A clinical trial study. Int J Nurs Sci 2023; 10(3):294-301. doi: 10.1016/j.ijnss.2023.06.009
- 25. Lee *G*, Hendriks JM. Improving outcomes in cardiovascular care—time to refocus on the hidden determinants of health? Eur J Cardiovasc Nurs 2023; 22(7):e53- e54. doi: 10.1093/eurj cn/zvad056
- 26. Li Y, Liu G, Liu C, Wang X, Chu Y, Li X, Yang W, Shen Y, Wu F, Zhang W. Effects of pharmacist intervention on community control of hypertension: A randomized controlled trial in Zunyi, China. Glob Health Sci Pract 2021; 9(4):890-904. doi: 1 0.9745/GHSP-D-20-00505
- 27. Maslakpak MH, Rezaei B, Parizad N. Does family involvement in patient education improve hypertension management? A single-blind randomized, parallel group,

- controlled trial. Cogent Med 2018; 5(1):1537063. doi: 10.1080/2 331205x.2018.1537063
- 29. Proia KK, Thota AB, Njie GJ, Finnie RK, Hopkins DP, Mukhtar Q, Pronk NP, Zeigler D, Kottke TE, Rask KJ, Lackland DT, Brooks JF, Braun LT, Cooksey T; Community Preventive Services Task Force. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med 2014; 47(1):86-99. doi: 10.1 016/j.amepre.2014.03.004
- 30. Ravera A, Carubelli V, Sciatti E, Bonadei I, Gorga E, Cani D, Vizzardi E, Metra M, Lombardi C. Nutrition and cardiovascular disease: finding the perfect recipe for cardiovascular health. Nutr 2016; 8(6):363. doi: 10.3390/nu806 0363
- 31. Reddy KS, Mathur MR. Global Burden of CVD: Prevalence, Pattern, and Trends. Handb Glob Health 2021; 423-437. doi: 1 0.1007/978-3-030-45009-0_24
- 32. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1):3-10. doi: 10.1056/NEJM2001010434 40101
- 33. Santschi V, Wuerzner G, Pais B, Chiolero A, Schaller P, Cloutier L, Paradis G, Burnier M. Team-Based care for improving hypertension management: a pragmatic randomized controlled trial. Front Cardiovasc Med 2021; 8:76 662. doi: 10.3389/fcvm.2021.760662
- 34. Shima R, Farizah MH, Majid HA. A qualitative study on hypertensive care behavior in primary health care settings in Malaysia. Patient Prefer Adherence 2014; 1597-609. doi: 10.214 7/ppa.s69680
- 35. Shyuan TH, Ariffin AA, Zulkefli NA, Mustapha FI. Predictors of Uncontrolled Hypertension among Patients Receiving Treatment from Public Primary Care Clinics in Pulau Pinang, Malaysia. Malays J Med Health Sci 2020; 16(4)-234-243.
- 36. Siang T, Hassali M, Fen N. The role of pharmacist in managing hypertension in the community: findings from a Community Based Study. Indian J Pharm Educ Res 2019; 53(3):553-61. doi: 10.5530/ijper.53.3.88

- 37. Tobari H, Arimoto T, Shimojo N, Yuhara K, Noda H, Yamagishi K, Iso H. Physician–pharmacist cooperation program for blood pressure control in patients with hypertension: a randomized-controlled trial. Am J Hypertens 2010; 23(10):1144-52. doi: 10.1038/ajh.2010.127
- 38. Wei TM, Omar MS. Self-management approaches among hypertensive residents in nursing homes in Malaysia. Malaysian family physician: Malays Fam Physician 2017; 12 (3):8-17.
- 39. Yang HH, Dhanjani SA, Chwa WJ, Cowgill B, Gee G. Disparity in Obesity and Hypertension Risks Observed Between Pacific Islander and Asian American Health Fair Attendees in Los Angeles, 2011–2019. J Racial Ethn Health Disparities 2023; 10(3):1127-37. doi: 10.1007/s40615-022-01300-y
- 40. Zhao PX, Wang C, Qin L, Yuan M, Xiao Q, Guo YH, Wen AD. Effect of clinical pharmacist's pharmaceutical care intervention to control hypertensive outpatients in China. Afr J Pharm Pharmacol 2012; 6(1):48-56. doi: 10.5897/AJPP11.633